Raymond James & Associates’s ResMed RMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $3.23M | Sell |
13,231
-6,949
| -34% | -$1.55M | ﹤0.01% | 1922 |
|
|
2024
Q2 | $3.86M | Buy |
20,180
+13,633
| +208% | +$2.77M | ﹤0.01% | 1774 |
|
|
2024
Q1 | $1.3M | Sell |
6,547
-295
| -4% | -$54.1K | ﹤0.01% | 2431 |
|
|
2023
Q4 | $1.18M | Buy |
6,842
+1,200
| +21% | +$184K | ﹤0.01% | 2426 |
|
|
2023
Q3 | $834K | Sell |
5,642
-16,028
| -74% | -$2.9M | ﹤0.01% | 2582 |
|
|
2023
Q2 | $4.73M | Buy |
21,670
+1,888
| +10% | +$421K | ﹤0.01% | 1518 |
|
|
2023
Q1 | $4.33M | Sell |
19,782
-252
| -1% | -$54.7K | ﹤0.01% | 1555 |
|
|
2022
Q4 | $4.17M | Sell |
20,034
-2,701
| -12% | -$593K | ﹤0.01% | 1523 |
|
|
2022
Q3 | $4.96M | Sell |
22,735
-1,493
| -6% | -$340K | 0.01% | 1384 |
|
|
2022
Q2 | $5.08M | Sell |
24,228
-1,271
| -5% | -$271K | 0.01% | 1401 |
|
|
2022
Q1 | $6.18M | Buy |
25,499
+2,310
| +10% | +$559K | 0.01% | 1352 |
|
|
2021
Q4 | $6.04M | Sell |
23,189
-2,482
| -10% | -$644K | ﹤0.01% | 1429 |
|
|
2021
Q3 | $6.77M | Sell |
25,671
-2,459
| -9% | -$672K | 0.01% | 1297 |
|
|
2021
Q2 | $6.93M | Sell |
28,130
-8,290
| -23% | -$1.74M | 0.01% | 1284 |
|
|
2021
Q1 | $7.07M | Sell |
36,420
-3,005
| -8% | -$603K | 0.01% | 1222 |
|
|
2020
Q4 | $8.38M | Buy |
39,425
+2,284
| +6% | +$455K | 0.01% | 1053 |
|
|
2020
Q3 | $6.37M | Buy |
37,141
+1,210
| +3% | +$223K | 0.01% | 1094 |
|
|
2020
Q2 | $6.9M | Buy |
35,931
+5,122
| +17% | +$838K | 0.01% | 1015 |
|
|
2020
Q1 | $4.54M | Buy |
30,809
+8,842
| +40% | +$1.41M | 0.01% | 1101 |
|
|
2019
Q4 | $3.4M | Sell |
21,967
-164
| -0.7% | -$23.6K | ﹤0.01% | 1506 |
|
|
2019
Q3 | $2.99M | Sell |
22,131
-3,903
| -15% | -$511K | ﹤0.01% | 1555 |
|
|
2019
Q2 | $3.18M | Buy |
26,034
+18,816
| +261% | +$2.08M | ﹤0.01% | 1503 |
|
|
2019
Q1 | $750K | Sell |
7,218
-8,755
| -55% | -$904K | ﹤0.01% | 2378 |
|
|
2018
Q4 | $1.82M | Buy |
15,973
+2,161
| +16% | +$232K | ﹤0.01% | 1720 |
|
|
2018
Q3 | $1.6M | Sell |
13,812
-368
| -3% | -$40.3K | ﹤0.01% | 1947 |
|
|
2018
Q2 | $1.47M | Buy |
14,180
+2,499
| +21% | +$253K | ﹤0.01% | 1964 |
|
|
2018
Q1 | $1.15M | Sell |
11,681
-271
| -2% | -$25.6K | ﹤0.01% | 2030 |
|
|
2017
Q4 | $1.01M | Buy |
+11,952
| New | +$987K | ﹤0.01% | 2123 |
|
|
2017
Q3 | – | Sell |
-2,576
| Closed | -$201K | – | 3475 |
|
|
2017
Q2 | $201K | Buy |
+2,576
| New | +$184K | ﹤0.01% | 2984 |
|
|
2017
Q1 | – | Sell |
-40,182
| Closed | -$2.49M | – | 3384 |
|
|
2016
Q4 | $2.49M | Sell |
40,182
-10,039
| -20% | -$615K | 0.01% | 1358 |
|
|
2016
Q3 | $3.25M | Buy |
50,221
+1,458
| +3% | +$97K | 0.01% | 1165 |
|
|
2016
Q2 | $3.08M | Sell |
48,763
-10,800
| -18% | -$637K | 0.01% | 1101 |
|
|
2016
Q1 | $3.44M | Sell |
59,563
-17,448
| -23% | -$988K | 0.01% | 1005 |
|
|
2015
Q4 | $4.13M | Sell |
77,011
-3,471
| -4% | -$196K | 0.01% | 897 |
|
|
2015
Q3 | $4.1M | Buy |
80,482
+59,411
| +282% | +$3.2M | 0.02% | 839 |
|
|
2015
Q2 | $1.19M | Buy |
+21,071
| New | +$1.33M | ﹤0.01% | 1636 |
|
|
2015
Q1 | – | Sell |
-15,403
| Closed | -$863K | – | 2393 |
|
|
2014
Q4 | $863K | Sell |
15,403
-10,534
| -41% | -$550K | ﹤0.01% | 1659 |
|
|
2014
Q3 | $1.28M | Sell |
25,937
-4,917
| -16% | -$250K | 0.01% | 1347 |
|
|
2014
Q2 | $1.56M | Buy |
30,854
+13,984
| +83% | +$693K | 0.01% | 1233 |
|
|
2014
Q1 | $754K | Sell |
16,870
-29,055
| -63% | -$1.31M | 0.01% | 1580 |
|
|
2013
Q4 | $2.16M | Sell |
45,925
-6,289
| -12% | -$318K | 0.02% | 916 |
|
|
2013
Q3 | $2.76M | Sell |
52,214
-4,286
| -8% | -$208K | 0.02% | 722 |
|
|
2013
Q2 | $2.55M | Buy |
+56,500
| New | +$2.68M | 0.02% | 691 |
|
Other funds holding RMD
Raymond James & Associates's RMD Position: Q3 2024 in Review
Raymond James & Associates reduced its ResMed (RMD) stake by 34% in Q3 2024, selling an estimated $1.55M and leaving 13,231 shares worth $3.23M. The position accounts for ﹤0.01% of the portfolio, ranked #1922.
Raymond James & Associates first reported a position in RMD in Q2 2013 and has held it in 43 quarters since. The position peaked at $8.38M in Q4 2020. 801 funds tracked by Wall St. Rank hold RMD as of Q3 2024.
- Raymond James & Associates held 13,231 shares of ResMed worth $3.23M as of Q3 2024.
- Raymond James & Associates sold 6,949 ResMed shares in Q3 2024, an estimated $1.55M.
- ResMed made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1922 holding.
- Raymond James & Associates first reported a position in ResMed in Q2 2013 and has held it in 43 quarters since.
- Raymond James & Associates's ResMed position peaked at $8.38M in Q4 2020.
- 801 funds tracked by Wall St. Rank held ResMed as of Q3 2024.
Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.